Virbac Stock

Virbac ROE

The Return on Equity (ROE) of Virbac (VIRP.PA) as of Aug 24, 2026 is 13.41 %. In the previous year, Return on Equity (ROE) was 13.93 % — a change of -3.72% (lower).

ROE

13.41 %

YoY

-3.72%

Last updated:

In 2026, Virbac's return on equity (ROE) was 13.41 %, a -3.72% increase from the 13.93 % ROE in the previous year.

The Virbac ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2018
4.37 EUR
Jan 1, 2019
9.96 EUR
Jan 1, 2020
21.91 EUR
Jan 1, 2021
15.61 EUR
Jan 1, 2022
14.53 EUR
Jan 1, 2023
13.47 EUR
Jan 1, 2024
13.93 EUR
Jan 1, 2025
13.41 EUR
The Virbac ROE history
YEARROEYoY
13.41 %-3.72%
13.93 %+3.38%
13.47 %-7.28%
14.53 %-6.91%
15.61 %-28.75%
21.91 %+120.05%
9.96 %+128.01%
4.37 %-839.88%
-0.59 %-108.07%
7.32 %+240.99%
2.15 %-85.45%
14.74 %—
Access this data via the Eulerpool API
Get Free API Key

Virbac Stock analysis

What does Virbac do? Virbac SA is a French company specializing in animal medicines and care products. The company was founded in 1968 by Pierre Richard Dick, who studied veterinary medicine at the École nationale vétérinaire d'Alfort and gained experience as a veterinarian. Since its founding, Virbac SA has been headquartered near Carros, France and operates worldwide. The business model of Virbac SA is to offer a wide range of products to veterinarians and pet owners, aiming to ensure optimal health, care, and quality of life for their pets. This includes everything from vaccines, diagnostics, and medications to grooming products that veterinarians and pet owners need to ensure optimal pet healthcare. Virbac SA has five main business areas, namely livestock, pets, horses, hygiene products, and specialties. The livestock sector includes products such as feed additives and antiparasitics tailored to the specific needs of cattle, pigs, poultry, and fish. In the pets sector, Virbac SA offers products specifically tailored to dogs, cats, birds, and other pets. This includes both disease prevention and treatment products. In the horse sector, the company offers products for the maintenance, care, and health of horses. Another division of Virbac SA is hygiene products. The company offers a wide portfolio of products and solutions that support both veterinarians and pet owners in ensuring the health and care of animals. This ranges from infection control products to animal-specific shampoos and grooming items. The specialties sector, on the other hand, includes specialized products such as targeted diagnostics, therapeutics, and dietary supplements. The constant focus on research and development also leads to innovative product launches that consistently meet the highest quality standards. An example of this is the scientifically developed dental hygiene product line that improves both the oral health and breath quality of dogs and cats. For this, Virbac SA also receives awards from the Veterinary Center for Clinical Medicine in Munich. Through a systematic international expansion strategy, Virbac SA is now present in more than 100 countries. The company employs over 4,800 people worldwide and achieved a turnover of 954 million euros in 2019. Overall, Virbac SA stands for consistently high product quality and a strong customer orientation. With a combination of expertise and extensive scientific research and development, particularly in the field of animal health and care, the company is an important player in the global animal medicine manufacturing market. Virbac is one of the most popular companies on Eulerpool.

ROE Details

Decoding Virbac's Return on Equity (ROE)

Virbac's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Virbac's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Virbac's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Virbac’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Virbac stock

Return on Equity (ROE) of Virbac is 13.41 % in 2026.

Return on Equity (ROE) of Virbac changed from 13.93 % to 13.41 %, representing a -3.72% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Virbac since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Virbac with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API
Get Free API Key

Profitability — Virbac

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Virbac